Research from M.A. Valantin and co-researchers yields new findings on HIV/AIDS.

According to a study from Paris, France, "To assess the impact of switching to tenofovir disoproxil fumarate + emtricitabine on lipid parameters. HIV-infected patients with plasma viral load < 400 copies/mL, fasted triglycerides from 2.3 to 11.4 mmol/L and/or fasted low-density lipoprotein (LDL)-cholesterol > 4.1 mmol/L were randomized to switch the nucleoside reverse transcriptase inhibitor (NRTI) backbone to fixed-dose combination tenofovir disoproxil fumarate + emtricitabine or to maintain the baseline antiretroviral regimen (the control group)."

"The study has been registered with ClinicalTrials.gov under the identifier NCT00323492. Ninety-one patients were included …